DaVita (DVA)
(Delayed Data from NYSE)
$139.01 USD
+0.87 (0.63%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $139.04 +0.03 (0.02%) 5:26 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.01 USD
+0.87 (0.63%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $139.04 +0.03 (0.02%) 5:26 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
by Zacks Equity Research
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop
by Zacks Equity Research
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
by Zacks Equity Research
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
by Zacks Equity Research
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution
by Zacks Equity Research
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
by Zacks Equity Research
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
by Zacks Equity Research
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.